Norwegian version of this page

Pharmacotherapy - Comparative effectiveness and new targets

The group's focus is twofold. We study the comparative effects of drug use and cellular mechanisms to identify potential points of attack for new drug treatments.

Clinical trials usually take place under the auspices of the pharmaceutical industry. When a new drug comes on the market it is usually uncertain how the new drug works compared to older drugs already in clinical use.

Our research revolves around examining active comparisons of two or more drugs to analyze clinical drug effects (both benefits and harm).

The group is also studying the cellular mechanisms for identifying possible new points of attack for drug therapy. Here is the main focus on new targets within cancer and type-2 diabetes.

Projects

Comparative drug effects

In this project we develop systematic reviews and meta-analyses of clinical trials. To analyze drug effects (both benefits and harm) we use advanced statistical methods (mixed treatment comparisons / network meta-analyses).

The purpose of the project is to investigate how much better one active drug intervention works in relation to another active comparison with a view to placing new drugs in a timely therapeutic context (drug class reviews).

Follow-up of long-term effects of drug use in registry studies

In this project we focus on long-term effects of drug use. We connect two or more health registers to study long-term effects of drug use. We will also develop methods to incorporate data from quality registers and electronic patient records in a good way.

A special focus will be on the side effects of drug use and reporting of such. Our goal is to achieve better documentation regarding clinical effectiveness (real time use) of drugs.

Cellular mechanisms possible attack points for drug treatment of cancer and type-2 diabetes

The project includes mapping of cellular signaling mechanisms of attack for new drug treatment of cancer.

In addition studied cellular mechanisms of insulin resistance in skeletal muscle cells and how these mechanisms can be affected - including the potential drugs that modulate metabolic nuclear receptors and by training.

Parts of the project is carried out in collaboration with the Musculoskeletal Research Group at the School of Pharmacy, University of Oslo.

Published Dec. 21, 2016 2:34 PM - Last modified Oct. 18, 2017 11:12 AM

Contact

Group leader

Visiting address
Department of Pharmacology
Sognsvannsveien 20,
Building A2/A3 3rd floor
Rikshospitalet

Postal address
Department of Pharmacology
Division of Diagnostics and Intervention
P.O.Box 1057, Blindern, 0316 Oslo